维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

13篇 您的检索式：作者名="Yutkin"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease re- cmTence in renal cell carcinoma after nephrectomy 显示文摘	Nisman B Yutkin V Nechushtan H	2010	Urology2010，76，2：	1
	2	Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease re- currence in renal cell carcinoma after nephrectomy显示文摘	Nisman B Yutkin V Neehushtan H	2010	Urology2010，76，2：	1
	3	Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy 显示文摘	Nisman B Yutkin V Nechushtan H	2010	Urology2010，76，2：	1
	4	Regeneration of myenteric plexus in the mouse colon after experimental denervation with benzalkonium chloride显示文摘	Hanani M Ledder O Yutkin V	2003	J Comp Neurol2003，462，3：	1
	5	Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer显示文摘	Yutkin V Chin J	2012	Expert Opin Investig Drugs2012，21，：	1
	6	Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy显示文摘	NISMAN B YUTKIN V NECHUSHTAN H	2010	Urology2010，76，2：	1
	7	Serum thymidine ki- nase IActivity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver 显示文摘	Nisman B Appelbaum L Yutkin V	2016	Anticancer Res2016，36，4：	1
	8	Circulating Tumor M2 Pyruvate Kinase and Thymidine Kinase 1 Are Potential Predictors for Disease Recurrence in Renal Cell Carcinoma After Nephrectomy显示文摘	Benjamin Nisman Vladimir Yutkin Hovav Nechushtan Ofer N. Gofrit Tamar Peretz Simon Gronowitz Dov Pode	2010	Urology2010，，2：	1
	9	Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy显示文摘	Nisman B Yutkin V Nechushtan H	2010	Urology2010，76，2：	1
	10	Apaziquone as an intravesical therapeutic agent for urothelialnon-muscle-invasive bladder cancer显示文摘	YUTKIN V CHIN J	2012	Expert Opin Investig Drugs2012，21，2：	1
	11	Enantioselective sorption of alcohols in a homochiral metal organic framework 显示文摘	SUH K S K YUTKIN M P DYBTSEV D N	2012	ChemCommun2012，48，：	1
	12	Modular,homochiral,porous coordination polymers:rational design,enantioselective guest exchange sorption and Ab initio calculations of host-guest interactions显示文摘	DYBTSEV D N YUTKIN M P SAMSONENKO D G	2010	Chem Eur J2010，16，10：	1
	13	Role of PCA3 test in clinical decision making for prostate cancer diagnosis显示文摘AIM: To assess the role of PCA3 urine test in the management of patients with suspected prostate cancer after repeat negative prostate biopsies.METHODS: Patients with suspected prostate cancer eitherdue to high or rising prostate specific antigen(PSA) levels and with a history of prostate biopsy who were candidates for repeat procedure were prospectively recruited to undergo PCA3 urine test. The recommendations on further management including the decision whether to proceed or not to the biopsy were made based on the PCA3 score. Patients' adherence with the recommendations and influence of the PCA3 test on clinical decision making were assessed. The contribution of the multivariate model was measured with a decision curve analysis. RESULTS: Three hundred and fifty-six patients were recruited to the study and underwent the PCA3 test. Twenty-six percent of 263 patients underwent prostate biopsy despite the low risk designation by PCA3 and 30% of 93 men did not proceed to biopsy despite a high risk result, rendering overall adherence of 73%. The variables that significantly correlated with adherence were positive family history of prostate cancer and PSA more than 10 ng/m L. Pre-test clinical stage, the number and the results of previous biopsies were not associated with the adherence. The decision curve analysis gave identical results for cut-off points of 25 and 35. On multivariate analysis the model that included PCA3 score, serum PSA, family history and result of the previous biopsy best performed with Area Under the Curve of 0.77. CONCLUSION: PCA3 urine test markedly outperforms PSA in a repeat biopsy setting. Urologists and patients demonstrate substantial confidence in this analysis and tend to follow its recommendations.	Vladimir Yutkin Ali Al-Zahrani Andrew Williams Guy Hidas Carlos Martinez Jonathan Izawa Dov Pode Joseph Chin	2015	World Journal of Clinical Urology2015，4，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费